Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials

EBioMedicine

Volumn 8, Issue , 2016, Pages 309-316

  Proietti, Marco ^a   Lane, Deirdre A ^a   Lip, Gregory Y H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

Chronic kidney disease; Clinical outcomes; Major bleeding; Non valvular atrial fibrillation; Stroke

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ATRIAL FIBRILLATION; CAUSE OF DEATH; CLINICAL TRIAL (TOPIC); COMORBIDITY; COMPLICATION; FEMALE; HUMAN; KIDNEY FUNCTION TEST; MALE; MIDDLE AGED; MORTALITY; ODDS RATIO; OUTCOME ASSESSMENT; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; THROMBOEMBOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CAUSE OF DEATH; CLINICAL TRIALS AS TOPIC; COMORBIDITY; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT OUTCOME ASSESSMENT; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; THROMBOEMBOLISM; WARFARIN;

EID: 84964637877     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.04.013     Document Type: Article

References (32)

1. Albers G.W., Diener H.-C., Frison L., Grind M., Nevinson M., Partridge S., Halperin J.L., Horrow J., Olsson S.B., Petersen P., Vahanian A. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005, 293:690-698. 10.1001/jama.293.6.690.
2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39:S1-266.
3. Apostolakis S., Guo Y., Lane D.A., Buller H., Lip G.Y.H. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur. Heart J. 2013, 34:3572-3579. 10.1093/eurheartj/eht328.
4. Banerjee A., Fauchier L., Vourc'h P., Andres C.R., Taillandier S., Halimi J.M., Lip G.Y.H. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley atrial fibrillation project. J. Am. Coll. Cardiol. 2013, 61:2079-2087. 10.1016/j.jacc.2013.02.035.
5. Banerjee A., Fauchier L., Vourc'h P., Andres C.R., Taillandier S., Halimi J.M., Lip G.Y.H. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley atrial fibrillation project. Chest 2014, 145:1370-1382. 10.1378/chest.13-2103.
6. Bonde A.N., Lip G.Y.H., Kamper A.-L., Hansen P.R., Lamberts M., Hommel K., Hansen M.L., Gislason G.H., Torp-Pedersen C., Olesen J.B. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease. J. Am. Coll. Cardiol. 2014, 64:2471-2482. 10.1016/j.jacc.2014.09.051.
7. Camm A., Lip G., De Caterina R., Savelieva I., Atar D., Hohnloser S., Hindricks G., Kirchhof P. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012, 33:2719-2747. 10.1093/eurheartj/ehs253.
8. Connolly S.J., Pogue J., Eikelboom J., Flaker G., Commerford P., Franzosi M.G., Healey J.S., Yusuf S. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037. 10.1161/CIRCULATIONAHA.107.750000.
9. De Caterina R., Husted S., Wallentin L., Andreotti F., Arnesen H., Bachmann F., Baigent C., Huber K., Jespersen J., Kristensen S.D., Lip G.Y.H., Morais J., Rasmussen L.H., Siegbahn A., Verheugt F.W.A., Weitz J.I. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Thromb. Haemost. 2013, 110:1087-1107. 10.1160/TH13-06-0443.
10. Fox C.S. Predictors of new-onset kidney disease in a community-based population. JAMA 2004, 291:844. 10.1001/jama.291.7.844.
11. Friberg L., Benson L., Lip G.Y.H. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur. Heart J. 2014, 297-306. 10.1093/eurheartj/ehu139.
12. Gage B.F., van Walraven C., Pearce L., Hart R.G., Koudstaal P.J., Boode B.S.P., Petersen P. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004, 110:2287-2292. 10.1161/01.CIR.0000145172.55640.93.
13. Halperin J.L. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am. Heart J. 2003, 146:431-438. 10.1016/S0002-8703(03)00325-9.
14. Hart R.G., Pearce L.A., Asinger R.W., Herzog C.A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2011, 6:2599-2604. 10.2215/CJN.02400311.
15. Kleinow M.E., Garwood C.L., Clemente J.L., Whittaker P. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J. Manag. Care Pharm. 2011, 17:523-530.
16. Kooiman J., van Rein N., Spaans B., van Beers K.A.J., Bank J.R., van de Peppel W.R., del Sol A.I., Cannegieter S.C., Rabelink T.J., Lip G.Y.H., Klok F.A., Huisman M.V. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. PLoS One 2014, 9. 10.1371/journal.pone.0094420.
17. Levey A.S., Becker C., Inker L.A. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA 2015, 313:837-846. 10.1001/jama.2015.0602.
18. Limdi N.A., Nolin T.D., Booth S.L., Centi A., Marques M.B., Crowley M.R., Allon M., Beasley T.M. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am. J. Kidney Dis. 2015, 65:701-709. 10.1053/j.ajkd.2014.11.004.
19. Lip G.Y.H. Preventing stroke in atrial fibrillation: the SPORTIF programme. Pathophysiol. Haemost. Thromb. 2005, 34(Suppl. 1):25-30. 10.1159/000083081.
20. Lip G.Y.H., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J.G.M. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010, 137:263-272. 10.1378/chest.09-1584.
21. Lip G.Y.H., Skjøth F., Rasmussen L.H., Larsen T.B. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J. Am. Coll. Cardiol. 2015, 65:1385-1394. 10.1016/j.jacc.2015.01.044.
22. Olesen J.B., Lip G.Y.H., Kamper A.-L., Hommel K., Køber L., Lane D.A., Lindhardsen J., Gislason G.H., Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl. J. Med. 2012, 367:625-635. 10.1056/NEJMoa1105594.
23. Olsson S.B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362:1691-1698.
24. Piccini J.P., Stevens S.R., Chang Y., Singer D.E., Lokhnygina Y., Go A.S., Patel M.R., Mahaffey K.W., Halperin J.L., Breithardt G., Hankey G.J., Hacke W., Becker R.C., Nessel C.C., Fox K.A.A., Califf R.M. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K ant. Circulation 2013, 127:224-232. 10.1161/CIRCULATIONAHA.112.107128.
25. Pokorney S.D., Simon D.N., Thomas L., Fonarow G.C., Kowey P.R., Chang P., Singer D.E., Ansell J., Blanco R.G., Gersh B., Mahaffey K.W., Hylek E.M., Go A.S., Piccini J.P., Peterson E.D. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry. Am. Heart J. 2015, 170:141-148, 148.e1. 10.1016/j.ahj.2015.03.017.
26. Potpara T.S., Lenarczyk R., Larsen T.B., Deharo J.-C., Chen J., Dagres N., Conducted by the Scientific Initiatives Committee, E.H.R.A., Conducted by the Scientific Initiatives Committee European Heart Rhythm Association Management of atrial fibrillation in patients with chronic kidney disease in Europe results of the European Heart Rhythm Association survey. Europace 2015, 17:1862-1867. 10.1093/europace/euv416.
27. Roldán V., Marín F., Fernández H., Manzano-Fernández S., Gallego P., Valdés M., Vicente V., Lip G.Y.H. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am. J. Cardiol. 2013, 111:1159-1164. 10.1016/j.amjcard.2012.12.045.
28. Rosendaal F.R., Cannegieter S.C., van der Meer F.J., Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 1993, 69:236-239.
29. Schiffrin E.L., Lipman M.L., Mann J.F.E. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97. 10.1161/CIRCULATIONAHA.106.678342.
30. Schulman S., Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 2005, 3:692-694. 10.1111/j.1538-7836.2005.01204.x.
31. Shields A.M., Lip G.Y.H. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. J. Intern. Med. 2015, 278:1-18. 10.1111/joim.12360.
32. White H.D., Gruber M., Feyzi J., Kaatz S., Tse H.-F., Husted S., Albers G.W. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch. Intern. Med. 2007, 167:239-245. 10.1001/archinte.167.3.239.